INTRODUCTION
Caveolae are flask-shaped plasma membrane invaginations thought to play a role in endocytosis, cholesterol homeostasis, intracellular signaling, and cell transformation. Caveolae are found in most cell types, but are particularly abundant in terminally differentiated cells such as adipocytes, endothelial cells, type 1 pneumocytes, fibroblasts, and muscle cells (1;2). The primary structural component of caveolae is caveolin-1, a 21-24 kDa integral membrane protein believed to act as a scaffolding protein within caveolae membranes (3) . Exogenous expression of caveolin-1 is sufficient to induce de novo caveolae formation (4;5) . Caveolae contribute to many cellular functions, including cholesterol binding and transport (6) (7) (8) , inhibition of signaling molecules (2;9), and suppression of oncogenic transformation (10;11) .
Transcriptional regulation of caveolin-1 expression is mediated by a variety of mechanisms (2;8;10-13) . For example, the mitogen activated kinase pathway protein ERK has been shown to control caveolin-1 expression at the transcriptional level in NIH 3T3 cells (10) whereas activation of src family kinases transcriptionally decrease caveolin-1 expression (2) . In addition, caveolin-1 transcription is up-regulated by sterol regulatory element binding protein-1 in response to free cholesterol, which results in caveolae formation and increased cholesterol efflux (12;13) . Conversely, high density lipoprotein exposure reduces caveolin-1 expression and prevents the uptake of oxidized cholesterol (14) . Cell growth also plays a role in caveolin-1 regulation, as rapidly dividing cells display decreased caveolin-1 expression levels, while confluent cells have dramatically upregulated caveolin-1 expression (11) . To date, little has been reported about posttranscriptional modes of caveolin-1 protein regulation.
Caveolin-2 is another member of the caveolin gene family (3) . Caveolin-2 is normally co-expressed with caveolin-1, and is thought to act as an accessory molecule, aiding in the formation of caveolae by forming hetero-oligomeric complexes with caveolin-1 (3;15). However, caveolin-2 alone is not sufficient to facilitate caveolae formation (3) . Caveolin-2 expression is linked to expression of caveolin-1. Caveolin-1 is thought to stabilize caveolin-2 protein, and thereby post-transcriptionally regulate its protein levels (15) .
Epithelial membrane protein 2 (EMP2) is a tetraspan protein recently identified as a novel regulator of caveolin-1 expression (16) . EMP2 is a member of the growth arrest specific-3/peripheral myelin protein-22 (GAS3/PMP22) family of proteins. Biologically, EMP2 plays an important role in blastocyst implantation with the uterine endometrium, in part through its direct association and regulation of αvβ3 integrin (17) . EMP2 controls cell membrane expression of integrins, glycosylphosphatidyl inositol-anchored, and class I major histocompatibility complex proteins (16) (17) (18) (19) . EMP2 resides at the plasma membrane within lipid raft domains, and this localization is distinct from caveolin-bearing membrane structures (16) . Previously, we have reported that recombinant overexpression of EMP2 in NIH 3T3 cells dramatically reduced expression of caveolin-1 and -2. Conversely, loss of EMP2 expression resulted in increased caveolin protein production (16) . These findings indicate an important role for EMP2 in maintaining plasma membrane structure and function.
Here, we further analyzed the mechanism of EMP2-mediated caveolin reduction. We show that EMP2 modulates caveolin-1 expression at both the transcriptional and translational levels, in both murine and human cell lines. Mechanistic analysis reveals that EMP2-mediated reduction of caveolin-1 protein involves aberrant intracellular compartmentalization and rapid degradation shortly after completion of translation. These observations thus describe a novel mechanism regulating caveolae formation.
MATERIALS AND METHODS

Cell Lines
NIH 3T3 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Omega Scientific, Tarzana, CA), 2mM L-glutamine, and 1mM sodium pyruvate (Invitrogen, Carlsbad, CA). NIH 3T3 cells stably expressing a FLAG-tagged murine EMP2 (3T3/EMP2) or a vector control (3T3/V) were cultured as previously described (20) . Cells were grown at 37°C in a humidified, 5% CO 2 atmosphere.
The human retinal pigmented epithelial cell line ARPE-19 (ATCC # CRL-2302) was grown in -DMEM/F12 (Invitogen) supplemented as above. To ectopically increase the expression of human EMP2, ARPE-19 (designated ARPE-19/EMP2) were stably transfected with pEGFP-hEMP2, a plasmid encoding a functional human EMP2-GFP fusion protein in the EcoR1 site of the pEGFP-N3 expression vector (17) . A vector control cell line was similarly prepared with pEGFP-N3, resulting in GFP expression alone (designated ARPE-19/V).
ARPE-19 transfectants were produced using FuGene 6 (Roche, Indianapolis, IN), and stable clones were selected using 700µg/ml Geneticin (Invitrogen).
Northern Blot Analysis
Total RNA was isolated using RNA purification and RNA cleanup kits (Qiagen, Valencia, CA). RNA (10 µg) was subjected to agarose electrophoresis (1.6% agarose/formaldehyde), transferred to a nylon membrane (Amersham Biosciences, Piscataway, NJ) by capillary action, and cross-linked by UV irradiation (Stratalinker, Stratagene, San Diego, CA). The following primers were used to generate cDNA probes: murine caveolin-1 CTACAAGCCCAACAACAAGGC/AGGA AGCTCTTGATGCACGGT; murine caveolin-2 ATGACGCCTACAGCCACCACAG/GCA AACAGGATACCCGCAATG. Probes were P-labeled using random primer synthesis kit (Stratagene) as described previously (20) . Membranes were pre-hybridized with Rapid-Hyb buffer (Amersham Biosciences) for 1 hour and then hybridized with labeled probe overnight at 65°C. Blots were washed in low stringency buffer (65°C, 2X sodium chloride/sodium citrate [SSC], and 0.1% sodium dodecyl sulfate [SDS] ) and high stringency buffer (65°C, 0.1X SSC, and 0.1% SDS), as needed, and exposed to x-ray film.
Antibodies
Anti-caveolin-1 antibodies were rabbit polyclonal anti-caveolin-1 antibody (N-20: Santa Cruz Biotech, Santa Cruz, CA), mouse monoclonal anti-caveolin-1-α and -β antibody (clone 2297: BD Biosciences), and rabbit polyclonal antiphospho-caveolin-1 (Tyr14: Cell Signaling Technology, Beverly, MA). Mouse anticaveolin-2 antibody (clone 65: BD Biosciences), mouse monoclonal anti-p53 antibody (2524: Cell Signaling Technology), rabbit polyclonal anti-beta actin antibody (ab8227: Abcam Inc., Cambridge, MA), goat anti-rabbit IgG horseradish peroxidase conjugate (4050-05: Southern Biotech, Birmingham, AL), and sheep anti-mouse IgG horseradish peroxidase conjugate (NA931: Amersham Biosciences) were also used.
Additional antibodies utilized for confocal microscopy included anti-γ-adaptin, anti-mouse CD107a (LAMP-1)-FITC, and anti-EEA-1 (all from BD Biosciences). Rhodamine conjugated goat anti-rabbit IgG (H+L), FITC conjugated anti-rabbit IgG (H+L), and Texas Red conjugated goat anti-mouse IgG were obtained from Jackson ImmunoResearch Laboratories West Grove, PA).
Immunoblot Analysis
Cells were lysed in Laemmli buffer, separated by SDS-PAGE, and then transferred to a nitrocellulose membrane (Amersham Biosciences). For EMP2 expression, cell lysates were additionally treated with PNGase (New England Biolabs) to remove N-linked glycans that interfere with the detection of EMP2 epitopes (20) . Membranes were stained with Ponceau S (Sigma Chemicals, St. Louis, MO) to determine transfer efficiency. Membranes were blocked with 10% low-fat milk or 5% bovine serum albumin in TBS containing 0.1% Tween-20 and probed with antibodies. Protein bands were visualized using a horseradish peroxidase-labeled secondary antibody, followed by chemiluminescence (ECL, Amersham Biosciences).
Subcellular Fractionation
3T3/V and 3T3/EMP2 cells (average cell number 3 x 10 6 ) were fractionated as previously described (21;22) . Briefly, cells were washed twice in a sucrose buffer (pH 7.4) containing 20mM Hepes, 1mM EDTA, 250mM sucrose, and protease inhibitors (Roche, Complete Mini Tablets). This sucrose buffer was used throughout all subsequent procedures that were carried out at 4 o C. Cells were resuspended in 1.0 ml of the same buffer, and homogenized with 3x10 strokes in a 2 ml Potter/Elvehjem Teflon pestle homogenizer.
The original cell homogenate was transferred into a 1.5 ml tube and centrifuged at 16,000 x g max for 15 min in an Eppendorf (Model 5415R) centrifuge. The resulting pellet was washed in 0.5 ml of sucrose buffer and recentrifuged as above.
The washing supernatant was combined with the supernatant of the initial pellet and was saved for preparation of the microsomal membrane fraction. The pellet was resuspended in 0.25ml of sucrose buffer and over-layered onto a 1.12 M sucrose cushion containing 20mM Hepes, 1mM EDTA and protease inhibitors and centrifuged at 101,000 x g max for 70 min. The resulting pellet containing the mitochondria, nuclei and cell debris, was collected, washed once and re-pelleted at 16,000 g max for 15 min and finally was resuspended in sucrose buffer and saved as nuclear fraction. The plasma membranes were collected at the sucrose interface, were washed once, re-centrifuged at 48,000 g max for 45 min and finally resuspended in sucrose buffer and saved as plasma membrane fraction. The initial supernatant was centrifuged at 212,000 g max for 70 min yielding the microsomal fraction in the pellet. Equal volume equivalents of each fraction were separated by immuoblot analysis as described above.
Phosphorylation Studies
To induce phosphorylation, cells were stressed with 600mM sucrose or 5mM H 2 0 2 for 10 minutes at 37°C (23) . Cells were then washed in PBS, harvested, and assayed by immunoblot. Sucrose and H 2 0 2 were diluted in complete growth medium.
Polysome Analysis
Cell lines were used at about 80% confluency to analyze polysome distribution. Cells were washed with icecold PBS containing 100µg/ml cycloheximide, removed using a cell scraper, and lysed in polysome lysis buffer (100mM KCl, 5mM MgCl 2 , 10mM HEPES [pH 7.4], 0.5% NP-40, 100µg/ml cycloheximide, and 5mM DTT). Nuclei were pelleted by centrifugation at 10,000 x g at 4°C for 10 min. The resulting supernatant was layered onto a 15-50% (wt/vol) linear sucrose gradient and centrifuged at 38,000 rpm for 2 h at 4°C in a Sorvall TH-61 rotor (Asheville, NC). Gradients were analyzed by passing the contents through a Density Gradient Fractionator (ISCO, Los Angeles, CA) to monitor continual OD 260 and then 1ml fractions were collected. Total RNA from each fraction was isolated using Trizol LS reagent (Invitrogen). Equal volumes from each fraction were used for Northern blot analysis, as described above.
Proteasome Inhibition
Proteasome inhibition studies were also performed 3T3/V and 3T3/EMP2 cell lines at about 80% confluency. Epoxomicin (Boston Biochem, Cambridge, MA) dissolved in DMSO was added to a final concentration of 100 nM, 1 µM, or 10 µM, or cells were given a DMSO control, or left untreated. Cells were incubated for 6 hours, harvested, lysed in lysis buffer (150mM NaCl, 10 mM Tris [pH 7.5], 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% NP-40, 1 µM PMSF, 1 µM pepstatin, 10 µM leupeptin, 2 mM sodium vanadate, and 5 µg/ml aprotinin), assayed for protein concentration, and subjected to Western blot analysis.
Metabolic Labeling and Immunoprecipitation
Metabolic labeling was performed by starvation for 20 minutes in DMEM without methionine and cysteine (supplemented with 5% dialyzed FBS, 2mM L-glutamine, 1mM sodium pyruvate, and antibiotics) followed by incubation for 1 hours with 240 µCi/ml [ 35 S] methionine and cysteine Pro-mix (Amersham). The media was replaced by DMEM supplemented with 2 mM methionine, and cells were analyzed at various time points ranging from 0-24 hours. Cells were harvested in PBS, and cell pellets were frozen in liquid nitrogen and stored at -80°C. To extract and denature proteins, cell pellets were lysed in 1% Nonidet P-40 containing 2 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 2 µg/ml, pepstatin, 10 mM iodoacetamide, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM HEPES, and 10 mM KCl). Lysates were sonicated, and then centrifuged to remove cell debris. Supernatants were collected, and protein concentration in the supernatant was then measured using the Bradford Assay Reagent (Bio-Rad). Samples were precleared using 8µg of agarose-conjugated normal rabbit IgG (Santa Cruz Biotech) by rotating for 1 hour at 4°C. Equal amounts of protein from each sample were then incubated overnight with 30 µg of anti-caveolin-1 rabbit polyclonal antibody and Protein A-agarose beads (both from Santa Cruz Biotech). Antibody-bound protein was collected by centrifugation, washed three times in lysis buffer, resuspended in 2X Laemmli buffer, boiled for 3 minutes, and then equal volumes were separated by SDS-PAGE. Resolved gels were then fixed, treated with Amplify Fluorographic Reagent (Amersham), dried under vacuum, and exposed using a Phosphor screen (Molecular Dynamics, Sunnyvale, CA). Analysis was performed using Typhoon 9410 (GE Healthcare Bio-Sciences Corp, Piscataway, NJ) and ImageQuant 5.2 software.
Lysosome Inhibition 3T3/EMP2 or 3T3/V cells were plated at 0.6 x 10 5 /well in 6 well plates and cultured for 2 days. Cells were then placed in serum free DMEM with lysosome inhibitors pepstatin A and leupeptin (both at 1 or 5 µM; Calbiochem) alone or in combination as previously described (24) .
Cells were incubated for 4 hours, and then harvested for Western blot analysis.
Bands were quantitated using Image J 1.36b software (25) .
Laser Confocal Microscopy 1 x 10 5 NIH 3T3 cells or 3T3/EMP2 were plated on 18-mm in diameter glass coverslips (Fisher Scientific, Pittsburgh, PA), and incubated for 48 hours. Cells were fixed in methanol, and blocked with 1% normal goat serum for 1 hour at room temperature. Samples were incubated with the primary antibodies, as listed in the figure legends, for one hour at room temperature, and visualized using a fluorescent secondary antibody. Confocal pictures were taken using a Zeiss LSM 510 confocal microscope at 600X magnification.
To measure caveolin-1 localization in different intracellular compartments, cells were processed for dual staining with antibodies for caveolin-1 and compartment markers (γ-adaptin, EEA-1, or LAMP-1). To assess the lysosomal compartment, cells prior to fixation were incubated for 1 hour in 0.5 µg/ml leupeptin and 0.5 µg/ml pepstatin (to reduce caveolin-1 degradation). The colocalization coefficient was quantitated by Zeiss LSM 5 PASCAL software (Carl Zeiss MicroImaging GmbH, Germany), and values represent the relative number of colocalizing pixels of caveolin compared to the total number of pixels above threshold. The mean colocalization coefficient was averaged from at least 3 independent images.
Statistics
Differences in caveolin levels and mean colocalization coefficients were evaluated using an unpaired Student's t test at a 95% confidence level (GraphPad Prism version 3.0; GraphPad Software, San Diego, CA).
RESULTS
EMP2 selectively regulates expression of caveolin-1 protein
Previously, our research group identified a role for EMP2 in regulating expression of caveolin-1 and caveolin-2 in NIH 3T3 cells with either increased or decreased EMP2 protein levels (16) . To further define this relationship, we performed quantitative titration analysis of caveolin-1 and caveolin-2 mRNA and protein (26) . Total RNA was isolated from NIH 3T3 cells stably transfected with either EMP2 (3T3/EMP2) or a vector control (3T3/V). Samples were diluted serially in 2-fold increments from 1:1 to 1:8, and then separated using electrophoresis and transferred to a nylon membrane. Membranes were probed for expression of caveolin-1 and caveolin-2 (Fig. 1A) . Strikingly, increased EMP2 levels reduced caveolin-1 steady state mRNA 3-fold and caveolin-2 mRNA levels by 2-fold. Ethidium bromide staining illustrated relative sample RNA amounts.
We next quantified steady state protein levels of caveolin-1, caveolin-2 and EMP2 in 3T3/EMP2 and 3T3/V cell lines (Fig. 1B) . For analysis of caveolin-1, 3T3/V total cell lysates were diluted serially in 2 fold increments from 1:1 to 1:64, while 3T3/EMP2 total cell lysates were diluted serially from 1:1 to 1:4. Caveolin-1 protein was decreased by 15-fold in 3T3/EMP2 cells. To analyze caveolin-2 protein levels, 3T3/V total cell lysate was serially diluted from 1:1 to 1:8, while 3T3/EMP2 total cell lysate was diluted serially from 1:1 to 1:4. Caveolin-2 protein levels were decreased 2-fold in 3T3/EMP2 cells.
Notably, changes in caveolin-1 mRNA and protein levels differed substantially, while changes in caveolin-2 mRNA and protein levels were comparable. To determine if caveolin-1 mRNA and protein level differences were significantly different, a Student's t test was performed. This analysis showed that changes in expression between caveolin-1 mRNA and protein were significant (p = 0.038; Fig.  1C ). Thus, EMP2 regulated expression of caveolin-1 at both the mRNA and protein levels. Conversely, regulation of caveolin-2 by EMP2 occurred only at the mRNA level.
EMP2 regulates expression of caveolin-1 in retinal pigment epithelium cells
To confirm the role of EMP2 in regulating expression of caveolin-1, we examined a human retinal pigmented epithelial cell line, ARPE-19, which endogenously express EMP2, caveolin-1 and caveolin-2. ARPE-19 cells were stably transfected with an EMP2 over-expression construct (ARPE-19/EMP2) or a vector control plasmid (ARPE-19/V), and selected for expression using Geneticin. Northern blot analysis revealed a 2-fold reduction in caveolin-1 mRNA when EMP2 is overexpressed ( Fig. 2A) . Conversely, caveolin-2 mRNA levels did not change. Ethidium bromide staining indicated equal RNA loading.
Western blot analysis was then used to examine changes in protein expression levels (Fig. 2B) . Cell extracts were assayed for expression of EMP2, caveolin-1, caveolin-2, and β-actin. Expression of the EMP2/GFP fusion protein is indicated by the presence of two bands, one at the expected 18kDa size of endogenous EMP2, and another at 46kDa, the expected size of an EMP2/GFP fusion protein. Consistent with our results in NIH 3T3 cells, caveolin-1 protein levels using an antibody specific for the full-length protein revealed a dramatic 96% reduction in caveolin-1 expression when EMP2 levels were increased by 80%. No change in caveolin-2 expression levels was observed (Fig. 2B) . β-actin was used to show equal protein loading.
EMP2 does not alter caveolin-1 translation efficiency
While a number of factors have been shown to control caveolin-1 transcription, little is known about posttranscriptional modes of caveolin-1 regulation (1). Given the dramatic ability of EMP2 to alter caveolin-1 protein levels, we next chose to examine how EMP2 was mediating this effect. To investigate if EMP2 was controlling the rate of caveolin-1 translation, we examined caveolin-1 polysome profiles in 3T3/EMP2 and 3T3/V cell lines. Figure 3A shows a typical polysome distribution for sucrose gradient eluents. Transcripts that were being translated at the time of extract preparation were polysome-associated and sedimented in fractions 6-10, with the most actively translated transcripts toward the bottom of the gradient. Distribution of mRNA among the gradient fractions is shown by ethidium bromide staining (Fig.  3B) . Northern blot analysis revealed that in 3T3/EMP2 cells, the majority of caveolin-1 mRNA was associated with polyribosomal fractions. In 3T3/V control cells, the majority of caveolin-1 mRNA was associated with polyribosomal fractions, while a small portion is associated with lessdense, polysome-free fractions. These results indicate that EMP2 did not regulate caveolin-1 protein levels by decreasing translation efficiency. As a control, gradient fractions were also analyzed for β-actin mRNA. Both cell lines showed similar, high rates of translation for β-actin.
EMP2 alters the subcellular distribution of caveolin-1.
In order to determine if EMP2 overexpression altered the subcellular distribution of caveolin-1, cells were separated using sucrose gradient centrifugation (Figure 4) . Similar to previously published reports (21;22), caveolin-1 was expressed in plasma membrane, microsomal, and nuclear fractions in 3T3/V cells ( Figure 4B, D) . Similarly, caveolin-1 is expressed in plasma membrane, microsomal, and nuclear fractions in 3T3/EMP2 cells ( Figure 4A, C) . Interestingly, there is no statistical difference in the caveolin-1 plasma membrane distribution between 3T3/V and 3T3/EMP2 cells (p=0.40).
However, 3T3/EMP2 cells does exhibit a significantly reduced microsomal fraction of caveolin-1 as compared to 3T3/V (p=0.0062).
EMP2 does not change the level of caveolin-1 phosphorylation
In order to understand the significance of EMP2 regulation of caveolin-1, phosphorylation of caveolin-1 was assessed. Caveolin-1 maintains an inactive state under normal cellular conditions but becomes phosphorylated at tyrosine 14 in response to cell signaling events (23) . 3T3/EMP2 and 3T3/V cell lines were subjected to hyper-osmotic or hydrogen peroxide-induced stress, treated with 600mM sucrose or 5mM H 2 0 2 for 10 min, and then subjected to immunoblot analysis (23) . As a control for expression levels, we also assayed the relative amount of total caveolin-1. β-actin documented equal protein loading.
As shown in Figure 5 , minimal caveolin-1 phosphorylation was detected in untreated 3T3/V cells, while no phosphorylated caveolin-1 was detected in untreated 3T3/EMP2 cells. Treatment of cells with either H 2 0 2 or sucrose (longer exposure) resulted in induction of caveolin-1 phosphorylation in 3T3/V cells. Phosphorylated caveolin-1 was also detectable in 3T3/EMP2 cells, although to a lesser degree.
When we normalized caveolin-1 phosphorylation in 3T3/EMP2 cells to the total level of caveolin-1 expression, caveolin-1 was phosphorylated to a similar extent in these cells (data not shown).
Consequently, caveolin-1 underwent normal levels of phosphorylation, and this mode of posttranslational modification would not appear to contribute to reduced caveolin-1 levels in 3T3/EMP2 cells.
EMP2 levels alter turnover of the longterm caveolin-1 pool
Regulation of protein turnover is a key factor in controlling protein expression (27) . Given the dramatically reduced protein levels of caveolin-1 in EMP2 over-expressing cells, we next chose to examine if EMP2 might be affecting caveolin-1 stability. To test this, we measured caveolin-1 turnover by pulse-chase analysis followed by immunoprecipitation of caveolin-1 protein (Figure 6 ). Strikingly, EMP2 upregulation dramatically accelerates caveolin-1 degradation. In 3T3/V cells, caveolin-1 half-life was approximately 5 h. However, upon overexpression of EMP2, the half life of caveolin-1 decreased to 100 min. In addition, after 24 h no significant levels of caveolin-1 were present in 3T3/EMP2 cells.
However, a sizeable fraction (33%) remained in 3T3/V cells. These findings indicate that EMP2 regulates caveolin-1 by accelerating turnover of the long-term caveolin-1 compartment.
EMP2 does not alter caveolin-1 proteasome mediated degradation.
One common mechanism for posttranslational regulation involves proteolysis, and a number of proteolytic mechanisms exist in cells (27) . One common system for the break down of proteins is via proteasome mediated ubiquitin-dependant degradation. Indeed, a caveolin-1 family member, caveolin-3, undergoes ubiquitination-proteasomal degradation when it is misfolded due to sequence mutations (28) . As EMP2 dramatically altered the stability of caveolin-1, we hypothesized that EMP2 might be increasing proteasome-mediated degradation of caveolin-1. To assess whether the proteasome was responsible for changes in caveolin-1 expression, we treated cells with epoxomicin, a potent and selective proteasome inhibitor, that should prevent degradation and therefore increase the levels of proteins targeted by the proteasome (29) . 3T3/EMP2 and 3T3/V cells were treated for 6 hours with 100nM, 1µM, or 10µM epoxomicin, a DMSO only vehicle control, or left untreated, and then assayed for protein levels of caveolin-1 and caveolin-2 by Western blot (30;31). p53, which is rapidly degraded in the absence of epoxomicin, serves as a control (32;33), while β-actin levels indicate equal protein loading. Titration of the proteasome inhibitor revealed no significant alternations (P<0.05) in total caveolin-1 and caveolin-2 protein levels in 3T3/EMP2 and 3T3/V cell lines (Fig. 7) . Note that visualization of caveolin-1 in the 3T3/EMP2 cell line required enhanced exposure as compared to the 3T3/V cell line. As a control, p53 levels were only detectable upon proteasome inhibition. Therefore, we conclude that EMP2 is not regulating caveolin-1 by altering proteasome-mediated degradation.
Protease inhibitors increase caveolin-1 expression
Another common pathway for proteolysis utilizes lysosomes (27;34) . Lysosomes are small organelles that mediate breakdown of proteins using proteases (27) , and caveolin proteins have been shown to associate with lysosomal markers (35;36) . To test the possibility that increased EMP2 may be targeting proteins to lysosomes, caveolin-1 levels were assessed in 3T3/EMP2 and 3T3/V cells treated for four hours with leupeptin (inhibitor of serine and thiol proteases) and/or pepstatin (aspartyl protease inhibitor). In 3T3/EMP2 cells, caveolin-1 expression increased 3-fold with pepstatin, but only modestly (50%) with leupeptin. A combination of the two inhibitors further increased caveolin-1 to 5-and 7-fold with 1 or 5 µM inhibitors, respectively (Figure 8) .
In 3T3/V cells, each inhibitor alone affected caveolin-1 levels minimally; combination of the inhibitors increased caveolin-1 by 2 to 2.5-fold with 1 or 5 µM inhibitors, respectively (Figure 8 ) but this did not reach statistical significance (p= 0.08). It should be noted that caveolin-1 immunoblot images show signal exposure equivalent to 3T3/EMP2 conditions. For quantitation with images in linear range, shorter times were used. These findings suggest that EMP2 promotes lysosomal degradation of caveolin-1, predominantly via aspartyl protease activity.
However, when we assessed early endosomes (EEA-1), more than 60% of EEA-1 signal colocalized with caveolin-1 in 3T3/EMP2 ( Figure 9B , and Table 1 ). In contrast, little caveolin-1 colocalized with EEA-1 in 3T3/V cells ( Figure 9B , and Table  1 ). Proteins targeted to early endosomes are either recycled back to the cell surface or to late endosomes/lysosomes (34;37).
To confirm caveolin-1 in the lysosomal compartment, 3T3/EMP2 cells were treated with the protease inhibitors pepstatin and leupeptin for one hour prior to staining to prevent caveolin-1 degradation.
Dramatically following treatment, caveolin-1 was colocalized with LAMP-1 ( Figure  9C ), representing 54% of the LAMP-1
Effect of EMP2 on the intracellular distribution of caveolin-1
To confirm the targeting of caveolin-1 to lysosomes by EMP2, we examined the intracellular localization of caveolin-1 in 3T3/EMP2 in comparison to 3T3/V cells. As in most cell types, caveolin-1 in 3T3/V cells is localized to the plasma membrane with minimal intracellular staining (data not shown; (18)). In contrast, 3T3/EMP2 cells displayed a punctate staining of the cytoplasm with little plasma membrane staining ( Figure 9A ). To identify the aberrant intracellular sites bearing caveolin-1, cells were co-stained for Golgi apparatus (γ-adaptin), early endosomes (EEA-1), and lysosomes (LAMP-1). In 3T3/EMP2 cells, γ-adaptin displayed normal peri-nuclear staining, but showed little colocalization with caveolin-1 (Fig. 9A) . 3T3/V cells exhibited greater colocalization (36%) than 3T3/EMP2 (15%), indicating that more caveolin-1 was retained in the Golgi apparatus in 3T3/V cells ( Figure 9A , and Table 1 ). + compartment (Table 1) .
In contrast, caveolin-1 in 3T3/V exhibited significantly less colocalization with lysosomes (23%; Figure 9C and Table 1 ). The increased colocalization of caveolin-1 within lysosomes in 3T3/EMP2 cells confirm that elevated EMP2 expression leads to increased trafficking of caveolin-1 into lysosomes via early endosomes.
DISCUSSION
Caveolin-1 is an integral component of plasma membrane caveolae and plays a role in numerous cellular functions including lipid transport, membrane trafficking of caveolin-2, and caveolae formation (4;5). Caveolin-1 expression is transcriptionally controlled by a variety of cellular factors, but post-transcriptional modes of regulation have yet to be identified. Our present findings demonstrate a new posttranscriptional mechanism of caveolin-1 regulation. Specifically, they indicate that caveolin-1 can be redirected after initial biosynthesis to EEA-1 and LAMP-1 compartments, which are associated with rapid proteolytic degradation.
Moreover, this early degradation fate is facilitated by increased levels of EMP2 expression.
Quantitative analysis of EMP2 overexpression on caveolin levels in NIH 3T3 cells indicated significant down-regulation of caveolin-1 expression mediated at both the RNA and protein levels, whereas decreases in caveolin-2 expression appear to be mediated only at the RNA level. Alternate expression profiles of caveolin-1 and caveolin-2 are not surprising, as caveolin-1 and caveolin-2 are differentially expressed in different cell types (3). Furthermore, Scherer et al have reported that NIH 3T3 cells transformed with v-Abl display dramatically decreased caveolin-1 levels, while caveolin-2 levels are unaffected (3) . Given the vital role of caveolin-1 in the formation of caveolae and the accessory role of caveolin-2, it is logical that expression of these proteins would be differentially regulated.
Association of caveolin-1 mRNA with polyribosomal subunits indicated that EMP2 did not alter caveolin-1 translation efficiency. Similarly, proteasome inhibitor assays excluded EMP2 dependent, proteasome-mediated degradation of caveolin-1 protein levels. Strikingly, when we analyzed caveolin-1 expression after 1 hour of biosynthetic labeling, its turnover rate was dramatically affected by EMP2 expression levels. 3T3/EMP2 cells (t 1/2 =1.5 h) exhibited 3.3 times faster caveolin-1 degradation compared to 3T3/V cells (t 1/2 = 5 h). When we next assessed lysosomal degradation of caveolin-1, normal levels of protein were restored following 4 hours of treatment with typical proteolytic inhibitors. Finally, confocal analysis revealed that in cells with elevated EMP2, caveolin-1 predominantly localized with EEA-1 and LAMP-1 compartments.
The process by which EMP2 promotes targeting of caveolin-1 to this degradation pathway is unknown. Lysosomal inhibitors modestly increased caveolin-1 levels at high concentrations, suggesting that the endogenous protein traffics to the lysosome.
Moreover, pepstatin treatment alone increased caveolin-1 in both 3T3/EMP2 and 3T3/V, suggesting that caveolin-1 degradation is primarily via aspartyl proteases. Previous studies have found that caveolin-1 can colocalize with lysosomes (35;36) . We observed that a small percentage of caveolin-1 was delivered to lysosomes in 3T3/V cells, suggesting that degradation of caveolin-1 via lysosomes is not an artifact of EMP2 overexpression. It is also interesting to note that confocal analysis and subcellular fractionation of 3T3/EMP2 cells reveal a significant fraction of caveolin-1 on the plasma membrane.
This suggests that caveolin-1 traffics to the membrane in these cells, where it is then consequently transported to lysosomal compartments.
Biologically, the reciprocal regulation of EMP2 and caveolin-1 levels has important implications for the surface receptor repertoire. For example, EMP2 strongly associates with P2X7 (38) . P2X7 is a ligand gated channel implicated in inflammasomes, a structure mediating cytoplasmic protein translocation to proteolytic endosomes (39;40) . One speculation is that EMP2 might play a role in structures that translocates proteins to an endosomal compartment and proteolytic fate.
It is known that caveolin-1 and EMP2 strongly modulate the surface availability and lipid raft association of large but distinct groups of membrane proteins. Le et al. reported that caveolin-1 acts as a negative regulator by preventing caveolae from internalizing (41;42) . Upon removal of caveolin-1, caveolae internalize more rapidly (41) . Consequently, by decreasing caveolin-1 protein levels, EMP2 may be facilitating increased internalization of caveolae-associated plasma membrane proteins. Conversely, increased EMP2 levels promotes the surface expression of several integrin isoforms, GPI-linked proteins, and MHC class 1 proteins (16) (17) (18) (19) .
The regulation by EMP2 of caveolin-1 expression thus would appear to profoundly reshape the cellular surface receptor repertoire, and its attendant responsiveness to the local environment.
Regulation of caveolin-1 expression by EMP2 may also play a role in cellular transformation. Reduced expression of caveolin-1 has been linked to cancer in a number of cell types (43) . Caveolin-1 was first discovered as a primary substrate for tyrosine phosphorylation in Rous sarcoma virus-transformed chicken embryonic fibroblasts, suggesting a role for caveolin-1 as a tumor suppressor protein (44) . Transformation of NIH 3T3 cells with various activated oncogenes (v-Abl, BcrAbl, and H-Ras (G12V)) downregulates caveolin-1 (10;26), and caveolin-1 is often reduced in breast and prostate cancer cell lines (45) (46) (47) (48) , sometimes in association with hypermethylation (45;49) . Mechanistically, the tumor suppressor role of caveolin-1 may reflect its inhibition of signaling activity of protooncogenes, presumably through its roles in surface receptor expression and signaling (43) . Indeed, specific knockdown of caveolin-1 is sufficient to confer a tumorigenic phenotype in NIH 3T3 cells (11) .
We recently reported that elevated expression of EMP2 is a central molecular feature of endometrial carcinoma with unfavorable outcome (50) . Closely related proteins in the PMP22/GAS3 family are also linked to malignant phenotype: PMP22 in pancreatic cancer (51) , osteosarcoma (52) (53) (54) , mammary carcinoma (55), schwannoma (56); EMP1 in brain tumors (57) ; and, EMP3 in prostate cancer (58), neuroblastoma, and glioma (59) . The basis of this association with aggressive malignant phenotype is largely unknown. However, we speculate that reciprocal downregulation of caveolin-1 may define one of the pathways linking overexpression of these tetraspan proteins to aggressive malignancy. . EMP2 does not inhibit caveolin-1 phosphorylation. Cells were treated with 600mM sucrose or 5mM H 2 0 2 for 10 minutes at 37°C to induce phosphorylation, and cell lysates were prepared and subjected to immunoblot analysis. Blots were probed with a phospho-specific caveolin-1 polyclonal antibody that recognizes only the tyrosine-14 phosphorylated form of caveolin-1. Immunoblotting with mAb 2297 shows total caveolin-1 protein levels. β-actin indicates equal protein loading. Experiment was performed three times with similar results. Forbes et. al Figure 6 Chase (h) A. 
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